Developments in T Cell Based Cancer Immunotherapies

Developments in T Cell Based Cancer Immunotherapies

Author: Paolo A. Ascierto

Publisher: Humana Press

Published: 2015-11-26

Total Pages: 315

ISBN-13: 3319211676

DOWNLOAD EBOOK

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.


Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book

Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book

Author: Daniel W. Lee

Publisher: Elsevier Health Sciences

Published: 2019-11-30

Total Pages: 246

ISBN-13: 0323755976

DOWNLOAD EBOOK

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.


Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2019-10-05

Total Pages: 89

ISBN-13: 0309490863

DOWNLOAD EBOOK

In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these "checkpoint" proteins and thwart the immune system's ability to recognize and attack cancer cells. To help promote an immune response to cancer, researchers have developed immune checkpoint inhibitors that enable T-cells to recognize cancer cells as foreign and to prevent deactivation of an immune system response. To examine the challenges and opportunities to develop combination cancer therapies that include immune checkpoint inhibitors, the National Cancer Policy Forum held a workshop on July 16â€"17, 2018, in Washington, DC. This workshop convened stakeholders with a broad range of expertise, including cancer researchers, clinicians, patient advocates, and representatives from industry, academia, and government. This publication summarizes the presentations and discussions from the workshop.


Co-signal Molecules in T Cell Activation

Co-signal Molecules in T Cell Activation

Author: Miyuki Azuma

Publisher: Springer Nature

Published: 2019-11-22

Total Pages: 326

ISBN-13: 9813297174

DOWNLOAD EBOOK

This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science.


Current Immunotherapeutic Strategies in Cancer

Current Immunotherapeutic Strategies in Cancer

Author: Matthias Theobald

Publisher: Springer Nature

Published: 2019-08-31

Total Pages: 190

ISBN-13: 3030237656

DOWNLOAD EBOOK

This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient’s cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.


??T Cell Cancer Immunotherapy

??T Cell Cancer Immunotherapy

Author: Marta Barisa

Publisher: Academic Press

Published: 2024-11-01

Total Pages: 0

ISBN-13: 9780443217661

DOWNLOAD EBOOK

?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation discusses the current pre-clinical and clinical ?d T cell landscape. The book not only focuses on the promises of what's to come, but also on the challenges faced by the field. Particular attention is given to summarizing recent advances on what is known about relevant areas of ?d T cell biology on summarizing the 'big picture' clinical situation, an up-to-date systematic clinical trial review covering autologous, allogeneic, engineered and non-engineered therapies, and perspectives on the types of cutting-edge gene-engineering that may be required to enhance the effect-size and durability of therapeutic efficacy. Content provides updated and comprehensive insights into the current state of ?d T cell immunotherapy, including discussions on the promise as well as challenges of the field that is of interest to existing translational ?d T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?d T cell immunotherapy in the clinic or are wishing to familiarize themselves with non-canonical lymphocyte immunotherapy.


Critical Developments in Cancer Immunotherapy

Critical Developments in Cancer Immunotherapy

Author: Sheykhhasan, Mohsen

Publisher: IGI Global

Published: 2024-08-28

Total Pages: 640

ISBN-13:

DOWNLOAD EBOOK

Cancer still poses a significant challenge in healthcare since traditional treatments often fail to produce desired results and patient outcomes. Conventional therapies, like chemotherapy and radiation, can have substantial side effects and may not always be able to eliminate cancer cells. Moreover, the heterogeneity of tumors and individual responses to treatment create barriers to achieving consistent and long-lasting outcomes. Critical Developments in Cancer Immunotherapy offers a compelling solution to these challenges by delving into the cutting-edge field of cancer immunotherapy. This book provides a comprehensive guide to the latest advancements in harnessing the body's immune system to fight cancer. Focusing on critical strategies like checkpoint inhibitors and CAR T-cell therapy, the book provides insights into novel approaches that offer greater precision and effectiveness in cancer treatment.


Advancements in Tumor Immunotherapy and Cancer Vaccines

Advancements in Tumor Immunotherapy and Cancer Vaccines

Author: Hilal Arnouk

Publisher: BoD – Books on Demand

Published: 2012-02-03

Total Pages: 232

ISBN-13: 9533079983

DOWNLOAD EBOOK

Harnessing the potential of the human body's own immune system to attack malignant tumor cells has been the goal of many scientific investigators in recent years, with advances in cancer biology and immunology enabling cancer immunotherapy to become a reality. World-class bench and clinical researchers have joined forces to collaborate and review current developments and trends in cancer immunology for the purposes of this book, and the result is a promising review of contemporary clinical treatments. In each chapter the authors present the scientific basis behind such therapeutic approaches, including cancer vaccines with special focus on prostate cancer, melanoma and novel approaches utilizing both innate and adaptive immune responses.


Gene and Cellular Immunotherapy for Cancer

Gene and Cellular Immunotherapy for Cancer

Author: Armin Ghobadi

Publisher: Springer Nature

Published: 2022-01-01

Total Pages: 371

ISBN-13: 303087849X

DOWNLOAD EBOOK

Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.


Advances in Tumor Immunology and Immunotherapy

Advances in Tumor Immunology and Immunotherapy

Author: Joseph D. Rosenblatt

Publisher: Springer Science & Business Media

Published: 2013-10-25

Total Pages: 369

ISBN-13: 1461488095

DOWNLOAD EBOOK

Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumor immunity and tumor evasion. In addition to emerging understanding of tumor evasion, new immune targets such as CTLA4 blockade, NK stimulatory receptors, manipulation of the antigen processing and presentation, cytokine and costimulatory responses all provide new possibilities for enhancing anti-tumor immunity even in tumors previously felt to be resistant to immune attack. Several of these strategies have already been realized in the clinic. The volume will explore evolving paradigms in antigen presentation, dendritic cell biology, the innate response and immunosuppressive mechanisms, and emerging strategies for manipulation of the immune system for therapeutic benefit that have realized success in neuroblastoma, leukemia, melanoma, lung cancer, and allogeneic transplantation. Early successes as well as failures will be highlighted to provide a snapshot of the state of clinical immunotherapy with an eye to future possibilities such as combination therapies, adoptive T-cell transfer, and the retargeting of immune cells via T-cell receptor engineering.